Anti-CTLA-4 Monoclonal Antibody IBI310 clinical trials
Also written IBI310.
Its developmentBy Innovent Biologics, step by step11 company-led studies, furthest phase 3: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-CTLA-4 Monoclonal Antibody IBI310 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-CTLA-4 Monoclonal Antibody IBI310 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2026 (5)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 3 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 5 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 10 · Other 7
Innovent Biologics (Suzhou) Co. Ltd. (9) · Shanghai Pulmonary Hospital, Shanghai, China (2) · Peking University (2) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · Shanghai Zhongshan Hospital (1) · Second Affiliated Hospital, School of Medicine, Zhejiang University (1) · Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. (1)
Often tested with
Tested in the same studies.
Sintilimab (6) · Bevacizumab (1) · Anti-PD-1/IL-2 Bispecific Antibody Fusion Protein IBI363 (1) · Cafelkibart (1) · Ipilimumab (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test Anti-CTLA-4 Monoclonal Antibody IBI310.
- Mar 2027A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCPhase 2 · Second Affiliated Hospital, School of Medicine, Zhejiang University
- Jul 2027Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Phase 1/2 · Shanghai Zhongshan Hospital
Studies
Open first, then newest update. How each study uses Anti-CTLA-4 Monoclonal Antibody IBI310 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Sintilimab Plus Ipilimumab N01 and Chemotherapy Versus Sintilimab Plus Chemotherapy as First-Line Treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma With PD-L1 CPS <5Not yet recruitingPhase 3The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolNCT07942285Written as sintilimab+IBI310+chemotherapy
- Phase Ib/II Multicenter Randomized Control Study of Peri-operative Treatment With Combination of CTLA-4, PD-1 Antibodies and Bevacizumab in Resectable HCC (Prophet)Not yet recruitingPhase 1/2Shanghai Zhongshan HospitalNCT07714317Written as IBI310+ sintilimab + bevacizumab
- A Prospective, Randomized Study of TACE Combined With Sintilimab, Bevacizumab, and Ipilimumab N01 Treating Advanced HCCRecruitingPhase 2Second Affiliated Hospital, School of Medicine, Zhejiang UniversityNCT07422753Written as CTLA-4 Antibody(ipilimumab N01)
- A Study to Evaluate the Efficacy and Safety of IBI310 and Sintilimab Combination Therapy in Patients With Hepatocellular Carcinoma as First-line Treatment.RecruitingPhase 2/3Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.NCT07490262Written as IBI310
- Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung CancerRecruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07410975Written as sintilimab+IBI310+chemotherapy
- Sintilimab Combined With IBI310 and Surufatinib for the Treatment of G3-NET and NEC (NESSIE)RecruitingPhase 2Peking UniversityNCT05165407Written as IBI310
- Efficacy of PD-1 Inhibitor Combination Therapy in Non-small Cell Lung Cancer Patients Who Have Not Achieved Major Pathologic Response After Neoadjuvant Immunotherapy: a Multicenter, Phase II Clinical TrialNot yet recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT06620822Written as IBI310+Sintilimab
- A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCCCompletedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04720716Written as IBI310
- A Study to Evaluate the Similarity in Pharmacokinetics and Safety of IBI310 and Ipilimumab(YERVOY)in Adult Healthy Chinese Male VolunteersCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04868760Written as IBI310
- IBI310 in Combination with Sintilimab in Patients with DNA Mismatch Repair Deficient (dMMR)/microsatellite Instability High (MSI-H) Locally-advanced or Metastatic Colorectal CancerTerminatedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT04258111Written as IBI310 (anti-CTLA-4 antibody)
- A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based ChemotherapyCompletedPhase 2Innovent Biologics (Suzhou) Co. Ltd.NCT04590599Written as IBI310
- IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract CancerStatus unknownPhase 1/2Innovent Biologics (Suzhou) Co. Ltd.NCT05653180Written as IBI310
- The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by SurgeryTerminatedPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT04277663Written as IBI310+IBI308
- A Study of IBI310 for the Treatment of Patients With Advanced Solid Tumors.CompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT03545971Written as IBI310
- IBI310 (Anti-CTLA-4) in Combination With Sintilimab in Patients With Non-small-cell Lung Cancer (NSCLC)CompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT05118334Written as IBI310
- IBI310 in Combination With Siltilimab in Subjects With Anti-PD-1/PD-L1 Resistance R/M NPCCompletedPhase 1Innovent Biologics (Suzhou) Co. Ltd.NCT04945421Written as IBI310
- Efficacy and Safety Evaluation of Sintilimab in Combination With IBI310 as Treatment in Patients With EBV-Positive Gastric CancerStatus unknownPhase 1/2Peking UniversityNCT04202601Written as IBI310
What changed recently
From the registry's own updates since Oct 19, 2026.